Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Middle East Pharmaceutical Industries Company (4016.SR)
Riyadh, SA
Middle East Pharmaceutical Industries Company (MEPIC), established in Riyadh, Saudi Arabia, in 1998, is a global pharmaceutical entity. The company's core activities encompass the entire lifecycle of generic medicines and various pharmaceutical products, from research and development to manufacturing and sales, catering to both local and international markets. Its business operations are strategically divided into private sector, public sector, and export divisions. MEPIC offers an extensive array of products designed to address a wide range of medical conditions. This includes dermatological treatments, remedies for respiratory ailments, central nervous system disorders, digestive issues, and musculoskeletal complaints, alongside medications for the urinary and reproductive systems. Furthermore, the company provides disinfectants and a diverse portfolio of therapeutic agents covering areas such as sexual health, diabetes, cardiovascular diseases, anti-infectives, anti-parasitics, pain relief, antiseptics, and general men's and women's health. These pharmaceutical and health products are supplied in numerous formats, including creams, ointments, syrups, capsules, tablets, gels, lotions, sprays, topical solutions, and personal hygiene items like hand sanitizers, mouthwashes, and soaps. In addition to its proprietary product lines, MEPIC leverages its manufacturing capabilities to offer contract manufacturing services. The company also specializes in cosmetic products, general health aids, and nutritional supplements. Originally known as Middle East Chemical Products Factory Company, the organization officially rebranded to Middle East Pharmaceutical Industries Company in January 2006.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.73% | +0.24% | -15.16% | -7.15% | -16.06% | -3.14% | -3.14% | -3.14% | -3.14% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%+16.9% ★ Q1'26: +33.7% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+21.5% ★ Q1'26: +38.9% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+14.6% ★ Q1'26: -1.9% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+23.5% ★ Q1'26: +23.6% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+22.7% ★ Q1'26: +23.5% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%-22.1% ★ Q1'26: +0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×0.59× Q1'26: 0.58× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
338.44M
est: 333.00M (+1.6%)
|
394.00M
est: 412.00M (-4.4%)
|
460.48M
est: 450.00M (+2.3%)
|
534.00M
534.00M – 534.00M
+18.7% YoY
|
626.00M
626.00M – 626.00M
+17.2% YoY
|
740.00M
740.00M – 740.00M
+18.2% YoY
|
861.00M
861.00M – 861.00M
+16.4% YoY
|
| EBITDA |
85.14M
est: 87.58M (-2.8%)
|
106.87M
est: 108.36M (-1.4%)
|
108.38M
est: 118.36M (-8.4%)
|
140.45M
140.45M – 140.45M
+18.7% YoY
|
164.65M
164.65M – 164.65M
+17.2% YoY
|
194.63M
194.63M – 194.63M
+18.2% YoY
|
226.46M
226.46M – 226.46M
+16.4% YoY
|
| EBIT |
77.53M
est: 78.85M (-1.7%)
|
91.03M
est: 97.56M (-6.7%)
|
108.38M
est: 106.56M (+1.7%)
|
126.45M
126.45M – 126.45M
+18.7% YoY
|
148.24M
148.24M – 148.24M
+17.2% YoY
|
175.23M
175.23M – 175.23M
+18.2% YoY
|
203.88M
203.88M – 203.88M
+16.4% YoY
|
| Net Income |
65.83M
est: 120.18M (-45.2%)
|
79.85M
est: 84.01M (-5.0%)
|
97.01M
est: 97.81M (-0.8%)
|
118.01M
118.01M – 118.01M
+20.7% YoY
|
140.01M
140.01M – 140.01M
+18.6% YoY
|
166.02M
166.02M – 166.02M
+18.6% YoY
|
212.22M
212.22M – 212.22M
+27.8% YoY
|
| SGA |
129.43M
est: 108.38M (+19.4%)
|
70.90M
est: 134.10M (-47.1%)
|
178.46M
est: 146.46M (+21.8%)
|
173.80M
173.80M – 173.80M
+18.7% YoY
|
203.75M
203.75M – 203.75M
+17.2% YoY
|
240.85M
240.85M – 240.85M
+18.2% YoY
|
280.23M
280.23M – 280.23M
+16.4% YoY
|
| EPS |
1.88
est: 3.43 (-45.2%)
|
2.28
est: 2.40 (-5.0%)
|
2.77
est: 2.79 (-0.9%)
|
3.37
3.37 – 3.37
+20.7% YoY
|
4.00
4.00 – 4.00
+18.6% YoY
|
4.74
4.74 – 4.74
+18.6% YoY
|
6.06
6.06 – 6.06
+27.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-21 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-17 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-14 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-10 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-05 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-04 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-03 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-26 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-19 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI Saudi Arabia ETF KSA | 0.10% | 672.3K | 0.75% |
| 2 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.01% | 79.1K | 0.55% |
| 3 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.01% | 36.5K | 0.74% |
| 4 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.01% | 19.3K | 0.56% |
| 5 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 192.2K | 0.39% |
| 6 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 9.7K | 0.44% |
| 7 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 145.2K | 0.29% |
| 8 | iShares Core MSCI EM IMI UCITS ETF EIMI.L | 0.00% | 305.6K | 0.18% |
| 9 | iShares Core MSCI EM IMI UCITS ETF EIMU.L | 0.00% | 12.5K | 0.18% |
| 10 | iShares International Country Rotation Active ETF CORO | 0.00% | 36.4K | 1.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mohammed Maher MohammedLotfi Al-Ghannam | Chief Executive Officer, MD & Director | 355.0K | male |
| Ammar Mamoun Abdul Wahab Al-Hajjah | Secretary of the Board of Directors | — | male |
| Fayez Basem Fayez Awada | Chief Marketing Officer | — | male |
| Hamoud Desan Mohammed Al-Anzi | Chief Administrative Officer | — | male |
| Moazam Ali Shah | Chief Financial Officer | — | male |
| Mohammed Ibrahim Metwally Salama | Chief Commercial Officer | — | male |
| Abdullah Al-Omairy | Compliance Manager | — | male |
| Rasheed Abdulaziz Mohammed Al Rasheed | Chief Operating Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4016.SR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
